Can a hormone reverse fatty liver disease? Here's what experts think
Researchers at Oklahoma University found that the hormone FGF21 can reverse fatty liver disease. The hormone signals the brain to improve liver function. It lowers liver fat and reverses fibrosis. The hormone also lowers cholesterol. This discovery could lead to new drugs for treating fatty liver disease. Clinical trials are showing good therapeutic benefits.
Fatty liver disease
is rising as a global health concern. Often considered a 'silent' disease as it shows few or no symptoms, fatty
liver
disease, however, can get serious, depending on its cause and progression. A new study has found that a certain hormone can
reverse fatty liver disease
.
A groundbreaking study by the researchers at the University of Oklahoma found that a hormone can reverse the effects of fatty liver disease in mice. The study is published in
Cell Metabolism
.
What is fatty liver disease?
Fatty liver, medically known as hepatic steatosis, is a condition in which fat builds up in the liver. There are two major types of fatty liver disease:
alcoholic fatty liver disease
(AFLD) and
nonalcoholic fatty liver disease
(NAFLD). AFLD, as the name suggests, occurs in people who drink large amounts of alcohol.
NAFLD, on the other hand, affects people who drink little or no alcohol. Though the cause of nonalcoholic fatty liver disease (NAFLD) is unknown, people who have type 2 diabetes, or prediabetes, obesity, are middle-aged or older, have high blood pressure, are prone to the disease.
How does the hormone control fatty liver disease?
The researchers found that the hormone FGF21 (fibroblast growth factor 21) can reverse
fatty liver disease
. The hormone works primarily by signaling the brain to improve
liver function
.
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
Google Brain Co-Founder Andrew Ng, Recommends: Read These 5 Books And Turn Your Life Around
Blinkist: Andrew Ng's Reading List
Undo
They delved into how FGF21 acts on the brain to influence liver metabolism. Understanding the mechanism of action of the hormone could become instrumental as a target for a new class of highly anticipated drugs that are in Phase 3 clinical trials.
'Fatty liver disease, or MASLD (metabolic dysfunction-associated steatotic liver disease), is a buildup of fat in the liver. It can progress to MASH (metabolic dysfunction-associated steatohepatitis) during which fibrosis and, ultimately, cirrhosis can occur.
MASLD is becoming a very big problem in the United States, affecting 40% of people worldwide, and there is currently only one treatment approved by the Food and Drug Administration to treat MASH.
A new class of drugs, based on FGF21 signaling, is showing good therapeutic benefits in clinical trials, but until now, the mechanism for how they work has been unclear,' Matthew Potthoff, Ph.D., the lead author and a professor of biochemistry and physiology at the University of Oklahoma College of Medicine and deputy director of OU Health Harold Hamm Diabetes Center said in a statement.
Fatty liver diet: Best and worst foods for your liver
The findings showed that FGF21 was effective at causing signaling in the model species that changed the liver's metabolism. The researchers found that this process lowered the liver's fat, and the fibrosis too was reversed. The hormone also sent a separate signal directly to the liver, specifically to lower cholesterol.
'It's a feedback loop where the hormone sends a signal to the brain, and the brain changes nerve activity to the liver to protect it.
The majority of the effect comes from the signal to the brain as opposed to signaling the liver directly, but together, the two signals are powerful in their ability to regulate the different types of lipids in the liver,' Potthoff added.
Similar to the GLP-1s (glucagon-like peptide 1) weightloss drugs that regulate blood sugar levels and appetite, FGF21 acts on the brain to regulate metabolism. Interestingly, both are hormones produced from peripheral tissues: GLP-1 from the intestine and FGF21 from the liver, and both work by sending a signal to the brain.
'It is interesting that this metabolic hormone/drug works primarily by signaling to the brain instead of to the liver directly, in this case. FGF21 is quite powerful because it not only led to a reduction of fat, but it also mediated the reversal of fibrosis, which is the pathological part of the disease, and it did so while the mice were still eating a diet that would cause the disease. Now, we not only understand how the hormone works, but it may guide us in creating even more targeted therapies in the future,' the lead author added.
Future-Proof Your Child with AI Skills | Limited Early Bird Seats – 33% OFF!
| WhatsApp: 9560500838
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
a day ago
- Time of India
PGI researchers give new hope for treatment of severe liver disease
Lucknow: Advanced scientific research conducted by scientists at Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS) has shown a new way to treat Non-Alcoholic Steatohepatitis (NASH) – a severe but common liver disease. Tired of too many ads? go ad free now The research, led by Rohit A Sinha, a scientist and associate professor in the endocrinology department, along with his team comprising Sana Raza and Pratima Gupta, proved that a naturally occurring hormone called dehydroepiandrosterone (DHEA) can help in checking liver damage caused by NASH by removing harmful fat from liver cells, reducing inflammation, and preventing liver damage. A Union health ministry document notes that NASH is the severest form of Non-Alcoholic Fatty Liver Disease (NAFLD). Terming it as "a silent epidemic", the document noted that NAFLD's community prevalence ranges from 9% to 32%, depending on age, gender, area of residence, and socioeconomic status. This means that up to three people out of 10 could have fatty liver or a related disease. What raises concerns is that 20% of people with NAFLD develop NASH. "DHEA is a parent hormone that acts as a precursor to sex hormones in humans. While scanning several case studies of NASH patients, we noted that the level of DHEA in them was on the lower side. Keeping this as the base, we proposed to study the impact of increasing this hormone in NASH patients with a significant extent of fibrosis – a symptom of NASH," said Sinha, adding that the study was published in the journal 'Molecular and Cellular Endocrinology'. "We began with animal studies. In the mouse model, we fed the experimental group with a NASH-inducing diet. When the condition was confirmed in them, we injected DHEA. The outcome showed that the severity of liver damage in 80% of the sample decreased by about 60%," he said. The results paved the way for a cellular study in which the researchers worked upon lab-grown human liver cells. "Here too, in the experimental group, we loaded the cells with excessive fat to create a NASH-like condition. Thereafter, we introduced DHEA and found that the fat percentage decreased by up to 80%," said Sinha. "The result has been heartening. We now look forward to clinical trials for hormone replacement therapy," he said.
Time of India
2 days ago
- Time of India
Beware of common & silent non-alcoholic liver disease
Bhopal: Non-alcoholic fatty liver disease can be a silent disease that shows few or no symptoms but can escalate to serious liver damage. It is a common ailment as well, one that you should be beware of. A state-wide initiative for non-alcoholic fatty liver disease screening began from June 1, including in Bhopal, targeting citizens aged above 30 years. According to a press release, this initiative focuses on awareness, early detection, treatment and prevention of liver-related ailments. The govt of Madhya Pradesh has established a partnership with the Institute of Liver and Biliary Sciences, New Delhi through an MoU. Earlier on May 21, the governor and the chief minister officially inaugurated this campaign on May 21. The programme involves initial screening by Asha workers for suspected NAFLD cases. They will collect data on BMI exceeding 23, waist circumference surpassing 80 cm in women and 90 cm in men, and diabetes history. Suspected cases will be reported to community health officers and workers. Participants will receive guidance on consuming home-available nutritious food and avoiding alcohol and tobacco, with regular follow-ups. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Encontre voos low-cost Voos | Anúncios de Pesquisa Saiba Mais Undo Medical professionals will conduct platelet count, SGOT (AST), SGPT (ALT) tests based on FIB-4 score calculations, followed by FIBROSCAN when medically indicated. Chief medical and health officer (CMHO) Bhopal, Dr Prabhakar Tiwari, emphasised that regular check-ups for non-communicable diseases can reduce illness severity. The non-communicable disease control programme and viral hepatitis control programme offer free services for liver-related issues. Previously, the Nirogi Kaya Abhiyan campaign screened for various non-communicable diseases, including high blood pressure, diabetes, cancer and non-alcoholic fatty liver disease, reaching over 50,000 people. Field health workers received training about liver function, related issues, symptom identification, dietary advice, exercise recommendations, lifestyle guidance and BMI calculations. The liver performs crucial functions continuously, including blood purification, toxin removal, nutrient storage, energy regulation, blood clotting maintenance, and production of bile, proteins, vitamins and minerals. Common liver conditions include fatty liver, fibrosis, hepatitis, cirrhosis and liver cancer.
News18
4 days ago
- News18
Techie, 24, Doesn't Drink, But Liver is already damaged. Internet Reacts
Last Updated: A study conducted by researchers at the University of Hyderabad discovered that 84% of IT employees are affected by Metabolic Dysfunction-Associated Fatty Liver Disease. In a shocking turn of events, a 24-year-old techie recently opened up about facing Liver problems despite being a non-alcoholic and a non-smoker. The reason? His poor diet and lifestyle choices. But this was not the only case, as the youngster later discovered that many of his friends working at Multi-National Companies like Amazon, Google or Microsoft, among others, are facing similar health issues, which could be alarming for all the corporate employees in India. Taking to Reddit, the user claimed that Liver problems are becoming 'disturbingly common' in the corporate and advised everyone to take tests and precautions according to the requirements. He wrote, 'I'm 24, work in tech, don't drink—and my liver is already damaged. Turns out, I'm not the only one. I spoke to several of my friends, all working in different big tech companies like Google, Amazon, PhonePe and Microsoft, in different cities, living what we call 'a normal tech life.' Yet, strangely, a common thread emerged in all those conversations—most of them were going through something they never expected to face in their twenties: elevated SGPT and SGOT levels." 'Initially, I assumed it was only me. After a routine blood test revealed that my liver enzymes were slightly higher, I was concerned but thought it was an isolated case. However, when I casually brought it up in conversations—over coffee breaks, the team calls, or over a weekend trip—I was surprised to hear comments like- Same here or I've also been requested to repeat my LFT," the post continued. He further added that most of the employees are in their mid-20s, which is 'supposedly their Physical peak' but have already been warned to take care of their liver, cut down oil, avoid processed food and reduce stress. 'It's become disturbingly common. The majority of us don't even drink or smoke heavily—yet our medical reports tell a different story," he added. Furthermore, the post highlighted the unhealthy lifestyle choices of youngsters these days due to the hectic work culture. He continued, 'We're often sitting for 10-12 hours a day, ordering in food because we're too tired to cook, skipping meals between back-to-back meetings, and sleeping poorly because of late-night screen time. When you combine caffeine, stress, and a sedentary lifestyle, you have the perfect storm for what doctors now refer to as NAFLD (Non-Alcoholic Fatty Liver Disease)." However, the user also marked significant measures for those dealing with liver problems. The post further reads, 'I've seen friends bounce back in just a few weeks with simple shifts-home-cooked food, 30 minutes of walking daily, hydration, fixed sleep, and conscious screen time reduction. What matters is catching it early and taking it seriously." Previously, a study conducted by researchers at the University of Hyderabad (UoH) discovered that 84 per cent of IT employees are affected by Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD), a condition linked to prolonged sitting, work stress, unhealthy diet, and lack of physical activity.
